Alnylam Pharmaceuticals
$145.019876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$145.01
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$5.20 (+3.72%) Today
$0.00 (0.00%) As of 8:00 PM EDT after-hours
Why Robinhood?
You can buy or sell ALNY and other stocks, options, ETFs, and crypto commission-free!
About ALNY
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. Read More The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA. The listed name for ALNY is Alnylam Pharmaceuticals, Inc. Common Stock.
Employees
1,323
Headquarters
Cambridge, Massachusetts
Founded
2002
Market Cap
16.82B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
643.48K
High Today
$145.25
Low Today
$138.73
Open Price
$140.00
Volume
500.95K
52 Week High
$167.33
52 Week Low
$73.32
Collections
Analyst Ratings
68%
of 22 ratings
Buy
68%
Hold
32%
Sell
0%
ALNY Earnings
-$2.28
-$1.52
-$0.76
$0.00
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Estimated
— per share
Actual
Expected Oct 29, Pre-Market